Biologics Market Report, Analysis, Opportunities by 2031
The biologics market size is projected to reach US$ 1,793.9 billion by 2031 from US$ 469.2 billion in 2023. The market is expected to register a CAGR of 18.2% in 2023–2031. Rising research and development (R&D) activities and increasing investments in biologics are likely to act as key trends in the biologics market.
Biologics Market Analysis
The increasing number of cases and diagnoses of chronic diseases triggers the need for sophisticated diagnostic and treatment drugs, which contributes significantly to the global biologics market. Discovery studies involving new compounds are undertaken to explore therapeutic options for patients who do not react to conventional treatments and demonstrate greater protection and effectiveness. Biologics are genetically modified drugs that target the specific site of inflammation that is triggered by the immune system in response to harmful stimuli. Given the emergence of COVID-19, governments in various countries also took measures to boost the healthcare industry and ensure biologics supply. In addition, researchers and scientists are studying various species and expression systems to improve the productivity of biologics. The development of cell lines and reagents to improve the yield of biologics manufacturing processes would further benefit biologics market growth. However, stringent regulations and high drug development costs limit the market growth.
Biologics Market Overview
Biologics is emerging as a dynamic and promising therapeutic segment in the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. The biologics market is growing continuously owing to enormous spending by pharmaceutical and biotechnology companies on improving their production facilities. The geriatric population is at high risk of developing chronic diseases such as cancer and autoimmune diseases, reflecting a need for biologics and drugs for treatment. Biologics such as monoclonal antibodies (MAbs), vaccines, recombinant proteins, antisense, RNAi, and molecular therapies are being studied for their potential to treat these medical conditions. MAbs are gaining popularity in therapeutic applications due to their specificity and effectiveness in targeting specific antigens. Therefore, the growing demand for therapies and the preference for outsourcing provide impetus to the biologics market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Biologics Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Biologics Market: Strategic Insights
![biologics-market](https://www.theinsightpartners.com/assets/rdimages/biologics-market-img1.png)
![Analyst Image](https://www.theinsightpartners.com/assets/mrinal_kerhalkar.jpg)
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
![Analyst Image](https://www.theinsightpartners.com/assets/images/speak_analyst.gif)
Biologics Market Drivers and Opportunities
Increasing Prevalence of Chronic Diseases Favor Biologics Market
According to a study titled "Chronic Disease: A Bio-Logical Approach," published in Ellerston Capital Limited, 41 million people worldwide die from chronic diseases every year, accounting for 74% of all deaths worldwide. Cancer was responsible for almost 10 million deaths in 2020, i.e., 1 in every 6 deaths. According to GLOBOCAN, 19.3 million cancer cases were registered worldwide in 2020, and the number is estimated to rise to 24.6 million by 2030. In addition, the prevalence of autoimmune diseases increases annually by 3–9%. The count of Alzheimer's disease cases is expected to reach 78 million by 2030 and 139 million by 2050. According to the World Health Organization (WHO), every year, ~17 million people across the world succumb to death due to noncommunicable diseases before the age of 70.
Biologics such as antibodies and vaccines offer more targeted treatment because they are designed to interact with the immune system in specific ways to deliver a therapeutic or prophylactic effect. Biological drugs have the promising potential to treat a few chronic autoimmune diseases by blocking the overactive components (proteins in many cases) of the immune system, which damage joints, skin, and other body parts. The treatment of cancer with biologics involves using the body's immune cells to kill cancerous cells; cytokines such as interferons, interleukins, and mAbs are the most commonly used biological therapies employed to treat cancer. Therefore, the increasing prevalence of chronic diseases drives the growth of the biologics market.
Evolution of Biotechnology Industry in Developing Regions to Create Opportunities for Biologics Market Growth
Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public–private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.
Biologics Market Report Segmentation Analysis
Key segments that contributed to the derivation of the biologics market analysis are product, application, source, and manufacturing.
- Based on product, the biologics market is divided into monoclonal antibodies, vaccines, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest share of the market in 2023, and it is further anticipated to register the highest CAGR during the forecast period.
- By application, the market is segmented into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023–2031.
- Based on source, the biologics market is divided into mammalian and microbial. The microbial segment held a larger share of the market in 2023. The mammalian segment is anticipated to register a higher CAGR during the forecast period.
- In terms of manufacturing, the market is bifurcated into outsourced and in-house. The outsourced segment held a larger share of the market in 2023, and it is estimated to register a higher CAGR during 2023–2031.
Biologics Market Share Analysis by Geography
The geographic scope of the biologics market report is mainly divided into five regions: North America, Asia Pacific, Europe, and the Middle East & Africa.
North America dominates the biologics market. Market growth in the region is attributed to the high prevalence of chronic diseases, numerous leading biopharmaceutical companies, favorable reimbursement policies, and significant investments in research and development. According to an article published in the JAMA Network, biologics R&D spending accounted for 37% of total drug R&D spending in the US. The number of prescriptions written for biologics and investments in the development of targeted drugs are on the rise in the country. Additionally, the approval of several novel biological drugs such as antisense, gene therapy, and RNAi therapeutics is expected to further drive the market growth. Asia Pacific is anticipated to record the highest CAGR during 2023–2031.
Biologics Market Report Scope
Biologics Market News and Recent Developments
The biologics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:
- Samsung Biologics, a global contract development and manufacturing organization (CDMO), announced a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs. Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences' ADC program designed to treat solid tumors. (Samsung Biologics, Press Release, February 2024)
- Selvita S.A. announced a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio. (Selvita, Press Release, March 2024)
Biologics Market Report Coverage and Deliverables
The "Biologics Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Biologics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Biologics market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter's Five Forces and SWOT analysis
- Biologics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the biologics market
- Detailed company profiles
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is expected to register a CAGR of 18.2% during 2023–2031.
The estimated value of the market would be US$ 1,793.9 billion by 2031.
Strategic initiatives by companies would bring attractive trends in the market in the coming years.
AbbVie Inc., Pfizer Inc., Samsung Biologics, ADMA Biologics Inc., WuXi Biologics, Catalent Inc, AGC Biologics, Crescendo Biologics Limited, Zumutor Biologics INC, Theriva Biologics, AstraZeneca, Amgen Inc., Avecia Biologics, and Quality Assistance s.a. are among the key players in the market.
North America dominated the market in 2023.
The increasing prevalence of chronic diseases and preference for outsourcing manufacturing operations are among the pivotal factors fueling the market growth.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Biologics Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Biologics Market – Key Market Dynamics
5.1 Biologics Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Increasing Prevalence of Chronic Diseases
5.2.2 Preference for Outsourcing Manufacturing Operations
5.3 Market Restraints
5.3.1 High Cost of Biologics
5.4 Market Opportunities
5.4.1 Evolution of Biotechnology in Developing Regions
5.5 Future Trends
5.5.1 Strategic Initiatives by Companies
5.6 Impact of Drivers and Restraints:
6. Biologics Market – Global Market Analysis
6.1 Biologics Market Revenue (US$ Million), 2021–2031
6.2 Biologics Market Forecast Analysis
7. Biologics Market Analysis – by Product
7.1 Monoclonal Antibodies
7.1.1 Overview
7.1.2 Monoclonal Antibodies: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Vaccine
7.2.1 Overview
7.2.2 Vaccine: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Recombinant Hormones/Proteins
7.3.1 Overview
7.3.2 Recombinant Hormones/Proteins: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Cell and Gene Therapy
7.4.1 Overview
7.4.2 Cell and Gene Therapy: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8. Biologics Market Analysis – by Application
8.1 Cancer
8.1.1 Overview
8.1.2 Cancer: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Autoimmune Diseases
8.3.1 Overview
8.3.2 Autoimmune Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
9. Biologics Market Analysis – by Source
9.1 Mammalian
9.1.1 Overview
9.1.2 Mammalian: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Microbial
9.2.1 Overview
9.2.2 Microbial: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
10. Biologics Market Analysis – by Manufacturing
10.1 Outsourced
10.1.1 Overview
10.1.2 Outsourced: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
10.2 In-house
10.2.1 Overview
10.2.2 In-house: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11. Biologics Market – Geographical Analysis
11.1 Overview
11.2 North America
11.2.1 North America Biologics Market Overview
11.2.2 North America: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3 North America: Biologics Market Breakdown, by Product
11.2.3.1 North America: Biologics Market – Revenue and Forecast Analysis – by Product
11.2.4 North America: Biologics Market Breakdown, by Application
11.2.4.1 North America: Biologics Market – Revenue and Forecast Analysis – by Application
11.2.5 North America: Biologics Market Breakdown, by Source
11.2.5.1 North America: Biologics Market – Revenue and Forecast Analysis – by Source
11.2.6 North America: Biologics Market Breakdown, by Manufacturing
11.2.6.1 North America: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.2.7 North America: Biologics Market – Revenue and Forecast Analysis – by Country
11.2.7.1 North America: Biologics Market – Revenue and Forecast Analysis – by Country
11.2.7.2 United States: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.2.1 United States: Biologics Market Breakdown, by Product
11.2.7.2.2 United States: Biologics Market Breakdown, by Application
11.2.7.2.3 United States: Biologics Market Breakdown, by Source
11.2.7.2.4 United States: Biologics Market Breakdown, by Manufacturing
11.2.7.3 Canada: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.3.1 Canada: Biologics Market Breakdown, by Product
11.2.7.3.2 Canada: Biologics Market Breakdown, by Application
11.2.7.3.3 Canada: Biologics Market Breakdown, by Source
11.2.7.3.4 Canada: Biologics Market Breakdown, by Manufacturing
11.2.7.4 Mexico: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.4.1 Mexico: Biologics Market Breakdown, by Product
11.2.7.4.2 Mexico: Biologics Market Breakdown, by Application
11.2.7.4.3 Mexico: Biologics Market Breakdown, by Source
11.2.7.4.4 Mexico: Biologics Market Breakdown, by Manufacturing
11.3 Europe
11.3.1 Europe Biologics Market Overview
11.3.2 Europe: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3 Europe: Biologics Market Breakdown, by Product
11.3.3.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Product
11.3.4 Europe: Biologics Market Breakdown, by Application
11.3.4.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Application
11.3.5 Europe: Biologics Market Breakdown, by Source
11.3.5.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Source
11.3.6 Europe: Biologics Market Breakdown, by Manufacturing
11.3.6.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.3.7 Europe: Biologics Market – Revenue and Forecast Analysis – by Country
11.3.7.1 Europe: Biologics Market – Revenue and Forecast Analysis – by Country
11.3.7.2 Germany: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.2.1 Germany: Biologics Market Breakdown, by Product
11.3.7.2.2 Germany: Biologics Market Breakdown, by Application
11.3.7.2.3 Germany: Biologics Market Breakdown, by Source
11.3.7.2.4 Germany: Biologics Market Breakdown, by Manufacturing
11.3.7.3 United Kingdom: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.3.1 United Kingdom: Biologics Market Breakdown, by Product
11.3.7.3.2 United Kingdom: Biologics Market Breakdown, by Application
11.3.7.3.3 United Kingdom: Biologics Market Breakdown, by Source
11.3.7.3.4 United Kingdom: Biologics Market Breakdown, by Manufacturing
11.3.7.4 Italy: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.4.1 Italy: Biologics Market Breakdown, by Product
11.3.7.4.2 Italy: Biologics Market Breakdown, by Application
11.3.7.4.3 Italy: Biologics Market Breakdown, by Source
11.3.7.4.4 Italy: Biologics Market Breakdown, by Manufacturing
11.3.7.5 France: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.5.1 France: Biologics Market Breakdown, by Product
11.3.7.5.2 France: Biologics Market Breakdown, by Application
11.3.7.5.3 France: Biologics Market Breakdown, by Source
11.3.7.5.4 France: Biologics Market Breakdown, by Manufacturing
11.3.7.6 Spain: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.6.1 Spain: Biologics Market Breakdown, by Product
11.3.7.6.2 Spain: Biologics Market Breakdown, by Application
11.3.7.6.3 Spain: Biologics Market Breakdown, by Source
11.3.7.6.4 Spain: Biologics Market Breakdown, by Manufacturing
11.3.7.7 Rest of Europe: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.7.1 Rest of Europe: Biologics Market Breakdown, by Product
11.3.7.7.2 Rest of Europe: Biologics Market Breakdown, by Application
11.3.7.7.3 Rest of Europe: Biologics Market Breakdown, by Source
11.3.7.7.4 Rest of Europe: Biologics Market Breakdown, by Manufacturing
11.4 Asia Pacific
11.4.1 Asia Pacific Biologics Market Overview
11.4.2 Asia Pacific: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3 Asia Pacific: Biologics Market Breakdown, by Product
11.4.3.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Product
11.4.4 Asia Pacific: Biologics Market Breakdown, by Application
11.4.4.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Application
11.4.5 Asia Pacific: Biologics Market Breakdown, by Source
11.4.5.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Source
11.4.6 Asia Pacific: Biologics Market Breakdown, by Manufacturing
11.4.6.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.4.7 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Country
11.4.7.1 Asia Pacific: Biologics Market – Revenue and Forecast Analysis – by Country
11.4.7.2 China: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.2.1 China: Biologics Market Breakdown, by Product
11.4.7.2.2 China: Biologics Market Breakdown, by Application
11.4.7.2.3 China: Biologics Market Breakdown, by Source
11.4.7.2.4 China: Biologics Market Breakdown, by Manufacturing
11.4.7.3 India: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.3.1 India: Biologics Market Breakdown, by Product
11.4.7.3.2 India: Biologics Market Breakdown, by Application
11.4.7.3.3 India: Biologics Market Breakdown, by Source
11.4.7.3.4 India: Biologics Market Breakdown, by Manufacturing
11.4.7.4 Japan: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.4.1 Japan: Biologics Market Breakdown, by Product
11.4.7.4.2 Japan: Biologics Market Breakdown, by Application
11.4.7.4.3 Japan: Biologics Market Breakdown, by Source
11.4.7.4.4 Japan: Biologics Market Breakdown, by Manufacturing
11.4.7.5 South Korea: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.5.1 South Korea: Biologics Market Breakdown, by Product
11.4.7.5.2 South Korea: Biologics Market Breakdown, by Application
11.4.7.5.3 South Korea: Biologics Market Breakdown, by Source
11.4.7.5.4 South Korea: Biologics Market Breakdown, by Manufacturing
11.4.7.6 Australia: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.6.1 Australia: Biologics Market Breakdown, by Product
11.4.7.6.2 Australia: Biologics Market Breakdown, by Application
11.4.7.6.3 Australia: Biologics Market Breakdown, by Source
11.4.7.6.4 Australia: Biologics Market Breakdown, by Manufacturing
11.4.7.7 Rest of APAC: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.4.7.7.1 Rest of APAC: Biologics Market Breakdown, by Product
11.4.7.7.2 Rest of APAC: Biologics Market Breakdown, by Application
11.4.7.7.3 Rest of APAC: Biologics Market Breakdown, by Source
11.4.7.7.4 Rest of APAC: Biologics Market Breakdown, by Manufacturing
11.5 Middle East and Africa
11.5.1 Middle East and Africa Biologics Market Overview
11.5.2 Middle East and Africa: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3 Middle East and Africa: Biologics Market Breakdown, by Product
11.5.3.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Product
11.5.4 Middle East and Africa: Biologics Market Breakdown, by Application
11.5.4.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Application
11.5.5 Middle East and Africa: Biologics Market Breakdown, by Source
11.5.5.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Source
11.5.6 Middle East and Africa: Biologics Market Breakdown, by Manufacturing
11.5.6.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.5.7 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Country
11.5.7.1 Middle East and Africa: Biologics Market – Revenue and Forecast Analysis – by Country
11.5.7.2 South Africa: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.2.1 South Africa: Biologics Market Breakdown, by Product
11.5.7.2.2 South Africa: Biologics Market Breakdown, by Application
11.5.7.2.3 South Africa: Biologics Market Breakdown, by Source
11.5.7.2.4 South Africa: Biologics Market Breakdown, by Manufacturing
11.5.7.3 Saudi Arabia: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.3.1 Saudi Arabia: Biologics Market Breakdown, by Product
11.5.7.3.2 Saudi Arabia: Biologics Market Breakdown, by Application
11.5.7.3.3 Saudi Arabia: Biologics Market Breakdown, by Source
11.5.7.3.4 Saudi Arabia: Biologics Market Breakdown, by Manufacturing
11.5.7.4 United Arab Emirates: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.4.1 United Arab Emirates: Biologics Market Breakdown, by Product
11.5.7.4.2 United Arab Emirates: Biologics Market Breakdown, by Application
11.5.7.4.3 United Arab Emirates: Biologics Market Breakdown, by Source
11.5.7.4.4 United Arab Emirates: Biologics Market Breakdown, by Manufacturing
11.5.7.5 Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.5.7.5.1 Rest of Middle East and Africa: Biologics Market Breakdown, by Product
11.5.7.5.2 Rest of Middle East and Africa: Biologics Market Breakdown, by Application
11.5.7.5.3 Rest of Middle East and Africa: Biologics Market Breakdown, by Source
11.5.7.5.4 Rest of Middle East and Africa: Biologics Market Breakdown, by Manufacturing
11.6 South and Central America
11.6.1 South and Central America Biologics Market Overview
11.6.2 South and Central America: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3 South and Central America: Biologics Market Breakdown, by Product
11.6.3.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Product
11.6.4 South and Central America: Biologics Market Breakdown, by Application
11.6.4.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Application
11.6.5 South and Central America: Biologics Market Breakdown, by Source
11.6.5.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Source
11.6.6 South and Central America: Biologics Market Breakdown, by Manufacturing
11.6.6.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Manufacturing
11.6.7 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Country
11.6.7.1 South and Central America: Biologics Market – Revenue and Forecast Analysis – by Country
11.6.7.2 Brazil: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.7.2.1 Brazil: Biologics Market Breakdown, by Product
11.6.7.2.2 Brazil: Biologics Market Breakdown, by Application
11.6.7.2.3 Brazil: Biologics Market Breakdown, by Source
11.6.7.2.4 Brazil: Biologics Market Breakdown, by Manufacturing
11.6.7.3 Argentina: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.7.3.1 Argentina: Biologics Market Breakdown, by Product
11.6.7.3.2 Argentina: Biologics Market Breakdown, by Application
11.6.7.3.3 Argentina: Biologics Market Breakdown, by Source
11.6.7.3.4 Argentina: Biologics Market Breakdown, by Manufacturing
11.6.7.4 Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
11.6.7.4.1 Rest of South and Central America: Biologics Market Breakdown, by Product
11.6.7.4.2 Rest of South and Central America: Biologics Market Breakdown, by Application
11.6.7.4.3 Rest of South and Central America: Biologics Market Breakdown, by Source
11.6.7.4.4 Rest of South and Central America: Biologics Market Breakdown, by Manufacturing
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in Biologics Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 AbbVie Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Samsung Biologics Co Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 WuXi Biologics Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Catalent Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AGC Biologics AS
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AstraZeneca Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Amgen Inc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Nitto Avecia
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Quality Assistance s.a.
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About The Insight Partners
List of Tables
Table 1. Biologics Market Segmentation
Table 2. Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Table 3. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 4. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 5. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Source
Table 6. Biologics Market – Revenue and Forecast to 2031 (US$ Million) – by Manufacturing
Table 7. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 8. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 9. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 10. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 11. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 12. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 13. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 14. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 15. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 16. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 17. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 18. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 19. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 20. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 21. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 22. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 23. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 24. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 25. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 26. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 27. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 28. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 29. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 30. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 31. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 32. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 33. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 34. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 35. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 36. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 37. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 38. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 39. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 40. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 41. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 42. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 43. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 44. France: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 45. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 46. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 47. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 48. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 49. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 50. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 51. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 52. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 53. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 54. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 55. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 56. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 57. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 58. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 59. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 60. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 61. China: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 62. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 63. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 64. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 65. India: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 66. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 67. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 68. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 69. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 70. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 71. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 72. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 73. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 74. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 75. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 76. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 77. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 78. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 79. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 80. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 81. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 82. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 83. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 84. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 85. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 86. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 87. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 88. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 89. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 90. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 91. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 92. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 93. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 94. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 95. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 96. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 97. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 98. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 99. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 100. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 101. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 102. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 103. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 104. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 105. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 106. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 107. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Country
Table 108. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 109. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 110. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 111. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 112. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 113. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 114. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 115. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 116. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Product
Table 117. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 118. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Source
Table 119. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million) – by Manufacturing
Table 120. Recent Organic Growth Strategies in Biologics Market
Table 121. Recent Inorganic Growth Strategies in the Biologics Market
List of Figures
Figure 1. Biologics Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Biologics Market Revenue (US$ Million), 2021–2031
Figure 5. Biologics Market Share (%) – by Product (2023 and 2031)
Figure 6. Monoclonal Antibodies: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Vaccine: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Recombinant Hormones/Proteins: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Cell and Gene Therapy: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Biologics Market Share (%) – by Application (2023 and 2031)
Figure 12. Cancer: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Infectious Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Autoimmune Diseases: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Biologics Market Share (%) – by Source (2023 and 2031)
Figure 17. Mammalian: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Microbial: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Biologics Market Share (%) – by Manufacturing (2023 and 2031)
Figure 20. Outsourced: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. In-house: Biologics Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Biologics Market Breakdown by Region, 2023 and 2031 (%)
Figure 23. North America: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 24. North America: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 25. North America: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 26. North America: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 27. North America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 28. North America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 29. United States: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 30. Canada: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 31. Mexico: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 32. Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 33. Europe: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 34. Europe: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 35. Europe: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 36. Europe: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 37. Europe: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 38. Germany: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. United Kingdom: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. Italy: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. France: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 42. Spain: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. Rest of Europe: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. Asia Pacific: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 45. Asia Pacific: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 46. Asia Pacific: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 47. Asia Pacific: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 48. Asia Pacific: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 49. Asia Pacific: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 50. China: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. India: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. Japan: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. South Korea: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 54. Australia: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. Rest of APAC: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 56. Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 57. Middle East and Africa: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 58. Middle East and Africa: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 59. Middle East and Africa: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 60. Middle East and Africa: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 61. Middle East and Africa: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 62. South Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 63. Saudi Arabia: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 64. United Arab Emirates: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 65. Rest of Middle East and Africa: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 66. South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 67. South and Central America: Biologics Market Breakdown, by Product (2023 and 2031)
Figure 68. South and Central America: Biologics Market Breakdown, by Application (2023 and 2031)
Figure 69. South and Central America: Biologics Market Breakdown, by Source (2023 and 2031)
Figure 70. South and Central America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
Figure 71. South and Central America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 72. Brazil: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 73. Argentina: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 74. Rest of South and Central America: Biologics Market – Revenue and Forecast to 2031(US$ Million)
Figure 75. Growth Strategies in Biologics Market
The List of Companies - Biologics Market
- AbbVie Inc.
- Pfizer Inc.
- Samsung Biologics
- ADMA Biologics, Inc.
- WuXi Biologics
- Catalent, Inc
- AGC Biologics
- AstraZeneca
- Amgen Inc.
- Avecia Biologics
- Quality Assistance s.a.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.